A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...
The blockbuster weight loss drugs that are taking the pharmaceutical market by storm may offer some additional benefits, ...
The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...
Newer medications to treat diabetes and obesity are saving lives, but those who need the injectable drugs the most, were the ...
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...
In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality and fell to fourth in 2022 before dropping to tenth in 2023.
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...
Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...
Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback